Literature DB >> 29246801

Regarding "Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea".

J S Mertens1, E M G J de Jong2, A Pandit3, M M B Seyger4, E P A H Hoppenreijs5, R M Thurlings6, M C Vonk6, J Wienke7, F van Wijk7, A van Royen-Kerkhof8, W Marut3, T R D Radstake9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29246801     DOI： 10.1016/j.jid.2017.11.032

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  3 in total

Review 1.  Immunopathogenesis of Pediatric Localized Scleroderma.

Authors:  Kathryn S Torok; Suzanne C Li; Heidi M Jacobe; Sarah F Taber; Anne M Stevens; Francesco Zulian; Theresa T Lu
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

Review 2.  Morphea: progress to date and the road ahead.

Authors:  Laila Abbas; Adrienne Joseph; Elaine Kunzler; Heidi T Jacobe
Journal:  Ann Transl Med       Date:  2021-03

3.  Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases.

Authors:  Morgan K Groover; Jillian M Richmond
Journal:  F1000Res       Date:  2020-10-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.